{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:23:38Z","timestamp":1794432218640,"version":"4.9.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1053\/j.semnuclmed.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:45Z","timestamp":1792096485000},"page":"1231-1247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical translation of targeted alpha therapy: Safety, dosimetry, radiation protection, and regulatory considerations"],"prefix":"10.1053","volume":"56","author":[{"given":"Narges","family":"Jokar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Pashazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik E","family":"Juweid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Najdian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmail","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-6521","authenticated-orcid":false,"given":"Felix M.","family":"Mottaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-9472","authenticated-orcid":false,"given":"Majid","family":"Assadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike M.","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.semnuclmed.2026.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: a review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.09.002_bib0002","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2967\/jnumed.117.204651","article-title":"\u03b1-emitters for radiotherapy: from basic radiochemistry to clinical studies-part 2","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.09.002_bib0004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/MNM.0000000000001832","article-title":"Selection of radionuclide(s) for targeted alpha therapy based on their nuclear decay properties","volume":"45","author":"Ree","year":"2024","journal-title":"Nucl Med Commun."},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Front Med."},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","article-title":"Implementing ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives","volume":"9","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0007","series-title":"Production and Quality Control of Actinium-225 Radiopharmaceuticals. IAEA-TECDOC-2057","year":"2024"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/pharmaceutics14010189","article-title":"212Pb: production approaches and targeted therapy applications","volume":"14","author":"Kokov","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.09.002_bib0009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.09.002_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12149-018-1317-1","article-title":"Introduction of targeted alpha therapy with radium-223 into clinical practice in Japan: learnings and implementation","volume":"33","author":"Hosono","year":"2019","journal-title":"Ann Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.09.002_bib0011","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.09.002_bib0012","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/pros.24857","article-title":"The safety and efficacy of targeted alpha therapy, Ac-225 prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"85","author":"Besiroglu","year":"2025","journal-title":"Prostate."},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.09.002_bib0013","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.09.002_bib0014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.09.002_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ekir.2020.12.006","article-title":"CKD after 225Ac-PSMA617 therapy in patients with metastatic prostate cancer","volume":"6","author":"Pelletier","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.09.002_bib0016","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Onco"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.09.002_bib0017","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted \u03b1-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"issue":"16_suppl","key":"10.1053\/j.semnuclmed.2026.09.002_bib0018","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2024.42.16_suppl.4020","article-title":"Safety, tolerability and efficacy of 212Pb-DOTAMTATE as targeted alpha therapy for unresectable or metastatic SSTR-positive GEP-NETs: a phase 2 study","volume":"42","author":"Strosberg","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.09.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105905","article-title":"First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate in malignant mesothelioma and other solid tumors","volume":"10","author":"Minchom","year":"2025","journal-title":"ESMO Open"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00259-018-4225-7","article-title":"Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma","volume":"46","author":"Kr\u00f3licki","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"34","key":"10.1053\/j.semnuclmed.2026.09.002_bib0021","doi-asserted-by":"crossref","first-page":"56311","DOI":"10.18632\/oncotarget.16910","article-title":"Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in models of renal cell carcinoma","volume":"8","author":"Hagemann","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.09.002_bib0022","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1535-7163.MCT-16-0251","article-title":"In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for acute myeloid leukemia","volume":"15","author":"Hagemann","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"10.1053\/j.semnuclmed.2026.09.002_bib0023","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.09.002_bib0024","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.119.234559","article-title":"Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA damage-repair-associated genes","volume":"61","author":"Kratochwil","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2967\/jnmt.121.262294","article-title":"Radiation safety considerations and clinical advantages of \u03b1-emitting therapy radionuclides","volume":"50","author":"Serencsits","year":"2022","journal-title":"J Nucl Med Technol"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0026","series-title":"Radiation Protection and Safety in Medical Uses of Ionizing Radiation. IAEA Safety Standards Series No. SSG-46","year":"2018"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0027","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0146645319838665","article-title":"ICRP publication 140: radiological protection in therapy with radiopharmaceuticals","volume":"48","author":"Yonekura","year":"2019","journal-title":"Ann ICRP"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0028","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1088\/0952-4746\/27\/3\/R01","article-title":"Radon exposure of the skin: i. biological effects","volume":"27","author":"Charles","year":"2007","journal-title":"J Radiol Prot"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.09.002_bib0029","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet No. 22 (abridged): radiobiology and dosimetry of \u03b1-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"issue":"3\u20134","key":"10.1053\/j.semnuclmed.2026.09.002_bib0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0146645318756253","article-title":"Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection","volume":"47","author":"Lassmann","year":"2018","journal-title":"Ann ICRP"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.09.002_bib0031","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0032","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40658-024-00635-1","article-title":"Quantitative SPECT\/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas","volume":"11","author":"Tulik","year":"2024","journal-title":"EJNMMI Phys"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22664-5","article-title":"Small-scale alpha-particle dosimetry methods using an iQID digital autoradiography imaging system","volume":"12","author":"Peter","year":"2022","journal-title":"Sci Rep"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.09.002_bib0034","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/RLU.0000000000002525","article-title":"225Ac prostate-specific membrane antigen posttherapy alpha imaging: comparing 2 and 3 photopeaks","volume":"44","author":"Usmani","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0035","first-page":"2113","article-title":"Dosimetry of a 238Pu-based \u03b1-particle irradiator and its biological application in a study of the bystander effect","volume":"31","author":"Dahle","year":"2011","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.09.002_bib0036","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1088\/1361-6498\/ab19d8","article-title":"Guidance on prevention of unintended and accidental radiation exposures in nuclear medicine","volume":"39","author":"Martin","year":"2019","journal-title":"J Radiol Prot"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.09.002_bib0038","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1681\/ASN.2004110945","article-title":"Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters","volume":"16","author":"Jaggi","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109008","article-title":"IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals","volume":"144-145","author":"Jalilian","year":"2025","journal-title":"Nucl Med Biol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.09.002_bib0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.apradiso.2004.06.013","article-title":"Cyclotron production of Ac-225 for targeted alpha therapy","volume":"62","author":"Apostolidis","year":"2005","journal-title":"Appl Radiat Isot"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2022.110337","article-title":"Regulating alpha-emitting radioisotopes and specific considerations for actinium-225 containing actinium-227","volume":"187","author":"Shober","year":"2022","journal-title":"Appl Radiat Isot."},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.09.002_bib0042","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3390\/ph16121679","article-title":"Targeted alpha therapy: all we need to know about 225Ac physical characteristics and production as a potential theranostic radionuclide","volume":"16","author":"Jalloul","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0043","series-title":"WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fourth Report. WHO Technical Report Series No. 1025, Annex 2","article-title":"International atomic energy agency and world health organization guideline on good manufacturing practices for radiopharmaceutical products","year":"2020"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0044","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41181-021-00123-2","article-title":"Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals","volume":"6","author":"Gillings","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.09.002_bib0045","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1007\/s00259-022-05738-4","article-title":"EANM guideline on quality risk management for radiopharmaceuticals","volume":"49","author":"Gillings","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2\u20134","key":"10.1053\/j.semnuclmed.2026.09.002_bib0046","article-title":"The 2007 recommendations of the international commission on radiological protection","volume":"37","year":"2007","journal-title":"ICRP Publication 103. Ann ICRP"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1058914","article-title":"Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis","volume":"10","author":"Gr\u00f8nnings\u00e6ter","year":"2023","journal-title":"Front Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.09.002_bib0048","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","article-title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial","volume":"17","author":"Saad","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1053\/j.semnuclmed.2026.09.002_bib0049","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2026.44.16_suppl.5010","article-title":"AcTION: phase 1 study of [225Ac]Ac-PSMA-617 in men with metastatic castration-resistant prostate cancer with or without prior [177Lu]Lu-PSMA radioligand therapy","volume":"44","author":"Emmett","year":"2026","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2026.09.002_bib0050","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s00259-017-3675-7","article-title":"Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review","volume":"44","author":"van der Pol","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"25","key":"10.1053\/j.semnuclmed.2026.09.002_bib0051","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.21.01208","article-title":"Salivary gland hypofunction and\/or xerostomia induced by nonsurgical cancer therapies: ISOO\/MASCC\/ASCO guideline","volume":"39","author":"Mercadante","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.09.002_bib0052","first-page":"548","article-title":"MASCC\/ISOO clinical practice statement: management of salivary gland hypofunction and xerostomia in cancer patients","volume":"32","author":"Hong","year":"2024","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0053","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands","volume":"8","author":"van Kalmthout","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0054","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","article-title":"Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT","volume":"46","author":"Rathke","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","article-title":"Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept","volume":"52","author":"Baum","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0056","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.09.002_bib0057","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.09.002_bib0058","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/diagnostics12081926","article-title":"Salivary gland toxicity of PSMA-targeted radioligand therapy with 177Lu-PSMA and combined 225Ac- and 177Lu-labeled PSMA ligands (TANDEM-PRLT) in advanced prostate cancer: a single-center systematic investigation","volume":"12","author":"Langbein","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0059","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41181-021-00124-1","article-title":"Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?","volume":"6","author":"Felber","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.09.002_bib0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/cancers17030405","article-title":"Long-term safety and survival outcomes of [225Ac]Ac-PSMA and [225Ac]Ac-\/[177Lu]Lu-PSMA (TANDEM) radioligand therapy in metastatic castration-resistant prostate cancer","volume":"17","author":"Perrone","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0061","series-title":"Consolidated Guidance about Materials Licenses: Program-Specific Guidance about Medical Use Licenses. NUREG-1556, Vol 9, Rev 3","year":"2019"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0062","series-title":"Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization during Clinical Development. Draft Guidance for Industry","year":"2025"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0063","first-page":"1","article-title":"Regulation (EU) No 536\/2014 on clinical trials on medicinal products for human use","volume":"L158","year":"2014","journal-title":"Off J Eur Union"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0064","unstructured":"European Medicines Agency. Clinical trials information system (CTIS). published january 31, 2022. updated may 17, 2022. accessed august 17, 2026. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-information-system."},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0065","series-title":"Concept Paper on Clinical Evaluation of Therapeutic Radiopharmaceuticals in Oncology. EMA\/CHMP\/451705\/2024","year":"2024"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0066","unstructured":"US Nuclear Regulatory Commission. Decay-in-storage. 10 CFR \u00a735.92."},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0067","series-title":"Nuclear Medicine Textbook: Methodology and Clinical Applications","first-page":"1039","article-title":"Recommendations for conducting clinical trials with radiopharmaceuticals","author":"Decristoforo","year":"2019"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0068","series-title":"Predisposal Management of Radioactive Waste from the Use of Radioactive Material in Medicine, Industry, Agriculture, Research and Education. IAEA Safety Standards Series No. SSG-45","year":"2019"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0069","series-title":"Regulations for the Safe Transport of Radioactive Material, 2025 Edition. IAEA Safety Standards Series No. SSR-6 (Rev. 2)","year":"2025"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.09.002_bib0070","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s00259-024-06640-x","article-title":"EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials","volume":"51","author":"Stokke","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0071","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40658-025-00831-7","article-title":"Feasibility study of 225Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT","volume":"13","author":"Zhang","year":"2026","journal-title":"EJNMMI Phys"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.09.002_bib0072","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/a-2179-6872","article-title":"On the use of artificial intelligence for dosimetry of radiopharmaceutical therapies","volume":"62","author":"Brosch-Lenz","year":"2023","journal-title":"Nuklearmedizin"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.09.002_bib0073","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2967\/jnumed.121.263239","article-title":"Nuclear medicine and artificial intelligence: best practices for evaluation (the RELAINCE guidelines)","volume":"63","author":"Jha","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.09.002_bib0074","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-022-05947-x","article-title":"An EANM position paper on the application of artificial intelligence in nuclear medicine","volume":"50","author":"Hustinx","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.09.002_bib0075","series-title":"Ethics and Governance of Artificial Intelligence for Health: WHO Guidance","year":"2021"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.09.002_bib0076","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/pharmaceutics15041051","article-title":"225Ac-labeled somatostatin analogs in the management of neuroendocrine tumors: from radiochemistry to clinic","volume":"15","author":"Rubira","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826001868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826001868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:54:32Z","timestamp":1794430472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299826001868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0001299826001868"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.09.002","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical translation of targeted alpha therapy: Safety, dosimetry, radiation protection, and regulatory considerations","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}